BCYC

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company pioneering a novel class of medicines called Bicycles®, which are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Headquartered in Cambridge, UK, with U.S. operations in Lexington, Massachusetts, Bicycle Therapeutics has developed a proprietary screening platform to generate Bicycles that combine the pharmacological properties of small molecules and antibodies, potentially offering advantages over both traditional drug modalities including better tissue penetration, rapid clearance, and improved targeting specificity. The company's lead program is zelenectide pevedotin (previously BT8009), a Bicycle Toxin Conjugate targeting Nectin-4, currently in pivotal Phase 3 trials for locally advanced or metastatic urothelial cancer. This first-in-class candidate has shown encouraging efficacy and tolerability in earlier trials. Bicycle's pipeline includes additional Bicycle Toxin Conjugates (BTCs) targeting various tumor-associated antigens, Bicycle TICA molecules designed to direct immune cells to tumors, and Bicycle Radionuclide Conjugates combining Bicycle targeting with radiotherapy. The modular platform enables rapid generation of new candidates. Bicycle molecules are designed to combine the advantages of multiple therapeutic modalities: they can penetrate tumors like small molecules, achieve highly selective target binding like antibodies, and rapidly clear from normal tissues reducing off-target exposure. The company has established strategic collaborations with major pharmaceutical companies including partnerships with AstraZeneca and Novartis that provide validation and funding. Bicycle Therapeutics has advanced multiple programs into clinical development and is working toward commercialization of its lead assets while continuing to expand its pipeline across oncology indications.